Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma

Zhang, B., Zhang, Y., Zhao, J., Wang, Z., Wu, T., Ou, W., Wang, J., Yang, B., Zhao, Y. X., Rao, Z., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0127-0 · Cited by 45

The Diagnostic Value of Cytokeratin 5/6, 14, 17, and 18 Expression in Human Non-Small Cell Lung Cancer

Chen, Y., Cui, T., Yang, L., Mireskandari, M., Knoesel, T., Zhang, Q., Pacyna-Gengelbach, M., & Petersen, I. (2011) · Oncology · doi:10.1159/000329098 · Cited by 43

Afatinib for the treatment of metastatic non-small cell lung cancer

Joshi, M., Rizvi, S., & Belani, C. P. (2015) · Cancer Management and Research · doi:10.2147/cmar.s51808 · Cited by 43

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma

Berger, A. H., Chen, M., Morotti, A., Janas, J. A., Niki, M., Bronson, R. T., Taylor, B. S., Ladanyi, M., Aelst, L. V., Politi, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079526 · Cited by 43

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer

Howe, G. A., Xiao, B., Zhao, H., Al‐Zahrani, K. N., Hasim, M. S., Villeneuve, J., Sekhon, H. S., Goss, G. D., Sabourin, L. A., Dimitroulakos, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150567 · Cited by 43

Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrone structure as potent anti-lung cancer agents

Wu, L., Wang, G., Liu, S., Wei, J., Zhang, S., Li, M., Zhou, G., & Wang, L. (2016) · Scientific Reports · doi:10.1038/srep35918 · Cited by 43

Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics

Minamimoto, R., Jamali, M., Gevaert, O., Echegaray, S., Khuong, A., Hoang, C. D., Shrager, J. B., Plevritis, S. K., Rubin, D. L., Leung, A. N. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17782 · Cited by 43

Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment

Cui, Z., Chen, S., Wang, Y., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.006 · Cited by 43

Targeting Protein Arginine Methyltransferase 5 in Disease

Richters, A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0089 · Cited by 43

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors

Ménard, L., Floc’h, N., Martin, M. J., & Cross, D. A. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2195 · Cited by 43

Microfluidics in Malignant Glioma Research and Precision Medicine

Logun, M. T., Zhao, W., Mao, L., & Karumbaiah, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700221 · Cited by 46

Relay tricyclic Pd( ii )/Ag( i ) catalysis: design of a four-component reaction driven by nitrene-transfer on isocyanide yields inhibitors of EGFR

Sawant, D. M., Sharma, S., Pathare, R. S., Joshi, G., Kalra, S., Sukanya, S., Maurya, A. K., Metre, R. K., Agnihotri, V. K., Khan, S., et al. (2018) · Chemical Communications · doi:10.1039/c8cc05845h · Cited by 43

Deconstructing tumor heterogeneity: the stromal perspective

Vickman, R. E., Faget, D. V., Beachy, P. A., Beebe, D. J., Bhowmick, N. A., Cukierman, E., Deng, W.-M., Granneman, J. G., Hildesheim, J., Kalluri, R., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27736 · Cited by 43

EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPIES FOR SOLID TUMOURS

den Eynde, M. V., Baurain, J. F., Mazzeo, F., & Machiels, J.-P. (2011) · Acta Clinica Belgica · doi:10.1179/acb.66.1.2062508 · Cited by 43

The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing

Roh, M. H. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.06.16 · Cited by 44

The epidermal growth factor receptor (EGRF) in lung cancer

Carcereny, E., Morán, T., Capdevila, L., Cros, S., Vilà, L., Gil, M. D. L. L., Remón, J., & Rosell, R. (2015) · Translational Respiratory Medicine · doi:10.1186/s40247-015-0013-z · Cited by 44

PROTACS: A technology with a gold rush-like atmosphere

Wang, Y., Lan, L., Wang, M., Zhang, J., Gao, Y., Shi, L., & Sun, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115037 · Cited by 44

Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study

Esteban, E., Majem, M., Aguillo, M. M., Martínez-Banaclocha, N., Dómine, M., Gómez-Aldaraví, L., Juan, Ó., Cajal, R., Arenas, M. C. G., & Provencio, M. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.02.003 · Cited by 42

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Okumura, S., Sasaki, T., Minami, Y., & Ohsaki, Y. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318233d686 · Cited by 43

EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells

Stella, G. M., Scabini, R., Inghilleri, S., Cemmi, F., Corso, S., Pozzi, E., Morbini, P., Valentini, A., Dore, R., Ferrari, S., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1444-y · Cited by 42

Synthesis of novel oleanolic acid and ursolic acid in C-28 position derivatives as potential anticancer agents

Tian, T., Liu, X., Lee, E.-S., Sun, J., Feng, Z., Zhao, L., & Zhao, C. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0868-8 · Cited by 42

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer

Husain, H., Scur, M. D., Murtuza, A., Bui, N. Q., Woodward, B. D., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0105 · Cited by 44

Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors

Hei, Y., Shen, Y. H., Wang, J., Zhang, H., Zhao, H., Xin, M., Cao, Y., Li, Y., & Zhang, S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.025 · Cited by 42

Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET

Oh, H., Lee, M.-H., Kim, E., Yoon, G., Chae, J., & Shim, J. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153014 · Cited by 42

Structural basis of the effect of activating mutations on the EGF receptor

Galdadas, I., Carlino, L., Ward, R. A., Hughes, S. J., Haider, S. M., & Gervasio, F. L. (2021) · eLife · doi:10.7554/elife.65824 · Cited by 42

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations

Wu, S., Yang, C.-H., Yu, C., Lee, J., Hsu, Y.-C., Chang, Y., Shih, J., & Yang, P. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.012 · Cited by 42

Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors

Zuo, M., Zheng, Y., Lu, S., Li, Y., & Zhang, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.034 · Cited by 42

Temporal Resolution of Autophosphorylation for Normal and Oncogenic Forms of EGFR and Differential Effects of Gefitinib

Kim, Y., Li, Z., Apetri, M. M., Luo, B., Settleman, J. E., & Anderson, K. S. (2012) · Biochemistry · doi:10.1021/bi300476v · Cited by 42

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

Liang, H., Xu, Y., Zhao, J., Chen, M., & Wang, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00761-z · Cited by 45

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.

Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

Belani, C. P. (2010) · Cancer Investigation · doi:10.3109/07357901003631072 · Cited by 41

Targeted Therapies in Lung Cancer

Chirieac, L. R., & Đačić, S. (2010) · Surgical pathology clinics · doi:10.1016/j.path.2010.04.001 · Cited by 41

Clinical cancer genomics: how soon is now?

Taylor, B. S., & Ladanyi, M. (2010) · The Journal of Pathology · doi:10.1002/path.2794 · Cited by 41

Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis

Hu, C., LIU, X., Chen, Y., Sun, X., Gong, Y., Geng, M., & Bi, L. (2012) · Oncology Reports · doi:10.3892/or.2012.1987 · Cited by 41

Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants

Zhang, H., Wu, W., Feng, C., Liu, Z., Bai, E., Wang, X., Lei, M., Cheng, H., Feng, H., Shi, J., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.036 · Cited by 41

GABABR-Induced EGFR Transactivation Promotes Migration of Human Prostate Cancer Cells

Xia, S., He, C., Zhu, Y., Wang, S., Li, H., Zhang, Z., Jiang, X., & Liu, J. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107854 · Cited by 41

Roco Proteins: GTPases with a Baroque Structure and Mechanism

Wauters, L., Versées, W., & Kortholt, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010147 · Cited by 41

Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy

Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42

Predicting ligand-dependent tumors from multi-dimensional signaling features

Hass, H., Masson, K., Wohlgemuth, S., Paragas, V. B., Allen, J. E., Sevecka, M., Pace, E. A., Timmer, J., Stelling, J., MacBeath, G., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0030-3 · Cited by 43

Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism

Basolo, A., Matrone, A., Elisei, R., & Santini, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.008 · Cited by 43

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

Hur, W., Velentza, A. V., Kim, S., Flatauer, L. J., Jiang, X., Valente, D., Mason, D. E., Suzuki, M., Larson, B., Zhang, J., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.062 · Cited by 41

Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab

Socinski, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0335 · Cited by 41

Molecular Therapy Targeting Sonic Hedgehog and Hepatocyte Growth Factor Signaling in a Mouse Model of Medulloblastoma

Coon, V. C., Laukert, T., Pedone, C. A., Laterra, J., Kim, K. J., & Fults, D. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0486 · Cited by 41

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers

Wang, X., Yin, H., Zhang, H., Hu, J., Lu, H., Li, C., Cao, M., Yan, S., & Cai, L. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0447-7 · Cited by 31

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

Deng, H., Lei, Q., Wang, C., Wang, Z., Chen, H., Wang, G., Yang, N. Y., Huang, D. A., Yu, Q., Yao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34627-5 · Cited by 40

Predicting miRNA-disease association via graph attention learning and multiplex adaptive modality fusion

Jin, Z., Wang, M., Tang, C., Zheng, X., Zhang, W., Sha, X., & An, S. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107904 · Cited by 40

Molecular docking, QSAR, and simulation analyses of EGFR-targeting phytochemicals in non-small cell lung cancer

Talukder, M. E. K., Atif, M. F., Siddiquee, N. H., Rahman, S., Rafi, N. I., Israt, S., Shahir, N. F., Islam, M. T., Samad, A., Wani, T. A., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139924 · Cited by 41

Oncogene‐dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma

Mito, J. K., Min, H. D., Ma, Y., Carter, J. E., Brigman, B. E., Dodd, L. G., Dankort, D. L., McMahon, M., & Kirsch, D. G. (2012) · The Journal of Pathology · doi:10.1002/path.4099 · Cited by 40

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

Ai, X., Sun, Y., Wang, H., & Lü, S. (2014) · Amino Acids · doi:10.1007/s00726-014-1716-0 · Cited by 40

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Lazzari, C., Spreafico, A., Bachi, A., Röder, H., Floriani, I., Garavaglia, D., Cattaneo, A., Grigorieva, J., Viganò, M. G., Sorlini, C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f17 · Cited by 40

Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors

Leary, A. F., de Castro, D. G., Nicholson, A. G., Ashley, S. E., Wotherspoon, A. C., O'Brien, M. E. R., & Popat, S. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.022 · Cited by 40

Proteomic analysis of phosphorylation in cancer

Ruprecht, B., & Lemeer, S. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.901156 · Cited by 41

Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms

Klingler, S., Guo, B., Yao, J., Yan, H., Zhang, L., Vaseva, A. V., Chen, S., Canoll, P., Horner, J. W., Wang, Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3122 · Cited by 40

A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3receptortyrosinekinasesignaling network

Telesco, S., Shih, A., Jia, F., & Radhakrishnan, R. (2011) · Molecular BioSystems · doi:10.1039/c0mb00345j · Cited by 40

Studies on the inhibition of feline EGFR in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors

Bergkvist, G. T., Argyle, D. J., Pang, L. Y., Muirhead, R. H., & Yool, D. A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.11.15525 · Cited by 40

Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions

Kuan, F., Li, S., Wang, C., Lin, M., Tsai, Y., & Yang, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13815 · Cited by 40

A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo

Shih, T., Liu, R., Fung, G., Bhardwaj, G., Ghosh, P., & Lam, K. S. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0690 · Cited by 40

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

Garon, E. B., Siegfried, J. M., Stabile, L. P., Young, P. A., Márquez‐Garbán, D. C., Park, D. J., Patel, R., Hu, E. H.-L., Sadeghi, S., Parikh, R. J., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.013 · Cited by 40

Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

Hyun, S. Y., Le, H. T., Nguyen, C.-T., Yong, Y.-S., Boo, H., Lee, H. J., Lee, J. S., Min, H.-Y., Ann, J., Chen, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32196-6 · Cited by 40

Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy

Zhang, Y., Zhang, L., Lin, X., Ke, L., Li, B., Xu, L., Lv, T., Li, Z., Chen, H., & Gao, Y. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.04.140 · Cited by 40

Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review

Cardoso, E., Guidi, M., Blanchet, B., Schneider, M. P., Decosterd, L. A., Buclin, T., Csajka, C., & Widmer, N. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000699 · Cited by 40

Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes

Nath, A., Lau, E. Y.-T., Lee, A. M., Geeleher, P., Cho, W. C. S., & Huang, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909998116 · Cited by 40

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles

Zanetti-Domingues, L. C., Bonner, S. E., Martin-Fernandez, M. L., & Huber, V. (2020) · Cells · doi:10.3390/cells9112505 · Cited by 41

Proteolysis targeting chimera ( PROTAC ) for epidermal growth factor receptor enhances anti‐tumor immunity in non‐small cell lung cancer

Wang, K., & Zhou, H. (2020) · Drug Development Research · doi:10.1002/ddr.21765 · Cited by 40

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC

Cheng, F., Chen, C., Tsai, W., Wang, B., Yu, M.-C., Hsia, T., Wei, Y.-L., Hsiao, Y.-C., Hu, D.-W., Ho, C.-Y., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01597-1 · Cited by 41

Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies

Kang, H., Lee, H., Kim, D., Kim, B., Kang, J., Kim, H. Y., Youn, H., & Youn, B. (2022) · Biomedicines · doi:10.3390/biomedicines10061308 · Cited by 40

Participation of Tom1L1 in EGF‐stimulated endocytosis of EGF receptor

Liu, N. S., Loo, L. S., Loh, E., Seet, L., & Hong, W. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.282 · Cited by 42

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma

Fisher, K. E., Jani, J. C., Fisher, S. B., Foulks, C., Hill, C. E., Weber, C. J., Cohen, C., & Sharma, J. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.05.003 · Cited by 40

Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target.

Su, J., Lin, P., Wang, C., & Chang, H. (2009) · PubMed · Cited by 40

Insertions and Deletions (Indels)

Sehn, J. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404748-8.00009-5 · Cited by 49

SPR biosensing: Cancer diagnosis and biomarkers quantification

Swami, S., Kayenat, F., & Wajid, S. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.109792 · Cited by 39

Finding the missing links in EGFR

Bessman, N. J., & Lemmon, M. A. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2221 · Cited by 39

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells

Komatsu, N., Fujita, Y., Matsuda, M., & Aoki, K. (2015) · Oncogene · doi:10.1038/onc.2015.16 · Cited by 43

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations

Ludovini, V., Bianconi, F., Pistola, L., Minotti, V., Chiari, R., Colella, R., Bellezza, G., Tofanetti, F. R., Siggillino, A., Baldelli, E., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1829-7 · Cited by 39

Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability

Wu, D.-W., Chen, C.-Y., Chu, C.-L., & Lee, H. (2015) · Oncogene · doi:10.1038/onc.2015.120 · Cited by 39

The next steps in next-gen sequencing of cancer genomes

Hayes, D. N., & Kim, W. Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci68339 · Cited by 40

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39

Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma

Wrzeszczyński, K. O., Frank, M. O., Koyama, T., Rhrissorrakrai, K., Robine, N., Utro, F., Emde, A., Chen, B., Arora, K. S., Shah, M. J., et al. (2017) · Neurology Genetics · doi:10.1212/nxg.0000000000000164 · Cited by 39

Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents

Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 39

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer

Hirano, T., Yasuda, H., Hamamoto, J., Nukaga, S., Masuzawa, K., Kawada, I., Naoki, K., Niimi, T., Mimasu, S., Sakagami, H., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1033 · Cited by 39

Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level

Hammoud, M. K., Yosef, H. K., Lechtonen, T., Aljakouch, K., Schuler, M., Alsaidi, W., Daho, I., Maghnouj, A., Hahn, S. A., El‐Mashtoly, S. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33682-7 · Cited by 42

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

Li, Y., Lin, M., Wang, S., Cao, B., Li, C., & Li, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842960 · Cited by 43

Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells

Yamauchi, Y., Izumi, Y., Yamamoto, J., & Nomori, H. (2013) · Phytotherapy Research · doi:10.1002/ptr.5056 · Cited by 39

Colloidal gold nanoparticle conjugates of gefitinib

Lam, A. T. N., Yoon, J., Ganbold, E., Singh, D. K., Kim, D., Cho, K.-H., Lee, S. Y., Choo, J., Lee, K., & Joo, S. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.08.021 · Cited by 39

Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non–small-cell lung carcinoma☆

Kim, J., Kang, D., Long, L. Z., Huang, S.-M., Yeo, M., Yi, E. S., & Kim, K. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.08.003 · Cited by 39

Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant

Qin, X., Li, Z., Yang, L., Liu, P., Hu, L., Zeng, C., & Pan, Z. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.003 · Cited by 39

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Dalurzo, M. L., Avilés‐Salas, A., Soares, F. A., Hou, Y., Li, Y., Строганова, А. М., Öz, B., Abdillah, A., Wan, H., & Choi, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s313669 · Cited by 39

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies

Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 38

Advancements in Global Phosphoproteomics Profiling: Overcoming Challenges in Sensitivity and Quantification

Muneer, G., Chen, C., & Chen, Y. (2024) · PROTEOMICS · doi:10.1002/pmic.202400087 · Cited by 40

Molecular Diagnostics of Lung Carcinomas

Đačić, S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0625-rair.1 · Cited by 38

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

Schuette, W., Schirmacher, P., Eberhardt, W., Fischer, J. R., von der Schulenburg, J.-M. G., Mezger, J., Schumann, C., Serke, M. H., Zaun, S., Dietel, M., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1149 · Cited by 38

Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression

Bidkhori, G., Moeini, A., & Masoudi‐Nejad, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048004 · Cited by 38

PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer Cells

Jiang, L., Lan, T., Chen, Y., Sang, J., Li, Y., Wu, M. C., Tao, Y., Wang, Y., Qian, H., & Gu, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061674 · Cited by 38

Type II cGMP-dependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells

Chen, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1507 · Cited by 38

Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial

Benlloch, S., Botero, M. L., Bertrán-Alamillo, J., Mayo, C., Giménez-Capitán, A. A., de Aguirre, I., Queralt, C., Ramírez, J. L., y Cajal, S. R., Klughammer, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089518 · Cited by 38

Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response

Ohler, Z. W., Difilippantonio, S., Carretero, J., Martin, P., Meskini, R. E., Iacovelli, A. J., Gumprecht, M., Kulaga, A., Guerin, T. M., Schlomer, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0736 · Cited by 38

EGFR and KRAS Mutations, and ALK Fusions: Current Developments and Personalized Therapies for Patients with Advanced Non-Small-Cell Lung Cancer

de Mello, R. A., Madureira, P., Carvalho, L. S., Araújo, A., O'Brien, M. E. R., & Popat, S. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.177 · Cited by 39

Pooled analysis of clinical outcome for EGFR TKI ‐treated patients with EGFR mutation‐positive NSCLC

Paz-Ares, L. G., Soulières, D., Moecks, J., Bāra, I., Mok, T. S. K., & Klughammer, B. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12278 · Cited by 38

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology

Roma, C., Esposito, C., Rachiglio, A. M., Pasquale, R., Iannaccone, A., Chicchinelli, N., Franco, R., Mancini, R., Pisconti, S., Luca, A. D., et al. (2013) · BioMed Research International · doi:10.1155/2013/385087 · Cited by 38

Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells

Wu, T., Liu, W., Guo, W., & Zhu, X. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.039 · Cited by 38

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156